Bellicum Pharmaceuticals, Inc.
(NASDAQ : BLCM)

( )
BLCM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.95%69.150.0%$1917.83m
NVAXNovavax, Inc. 9.93%146.5196.5%$1301.01m
SRNESorrento Therapeutics, Inc. -4.38%12.441.5%$767.50m
GILDGilead Sciences, Inc. 0.47%68.501.0%$580.36m
AMGNAmgen, Inc. 0.36%239.711.3%$465.88m
REGNRegeneron Pharmaceuticals, Inc. 0.28%612.572.7%$378.37m
VRTXVertex Pharmaceuticals, Inc. 0.05%267.291.9%$351.81m
BIIBBiogen, Inc. 0.32%289.451.4%$344.47m
ILMNIllumina, Inc. -1.69%347.563.5%$340.75m
BNTXBioNTech SE -3.32%68.640.0%$334.95m
ATNMActinium Pharmaceuticals, Inc. -1.21%9.7913.3%$231.53m
EBSEmergent BioSolutions, Inc. -1.09%133.476.4%$198.26m
VXRTVaxart, Inc. 0.55%9.140.0%$194.27m
MCRBSeres Therapeutics, Inc. -4.62%27.263.6%$181.12m
ALXNAlexion Pharmaceuticals, Inc. 1.06%102.971.9%$162.43m

Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.